WO2004106519A3 - Mrp8/mrp14 inhibitoren und ihre verwendung zur prävention und/oder behandlung von hypertrophen narben und keloiden - Google Patents

Mrp8/mrp14 inhibitoren und ihre verwendung zur prävention und/oder behandlung von hypertrophen narben und keloiden Download PDF

Info

Publication number
WO2004106519A3
WO2004106519A3 PCT/EP2004/006012 EP2004006012W WO2004106519A3 WO 2004106519 A3 WO2004106519 A3 WO 2004106519A3 EP 2004006012 W EP2004006012 W EP 2004006012W WO 2004106519 A3 WO2004106519 A3 WO 2004106519A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrp14
mrp8
inhibitors
keloids
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/006012
Other languages
English (en)
French (fr)
Other versions
WO2004106519A2 (de
Inventor
Andreas Goppelt
Stephanie Fritz
Michaela Bittner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Switch Biotech AG
Original Assignee
Switch Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switch Biotech AG filed Critical Switch Biotech AG
Publication of WO2004106519A2 publication Critical patent/WO2004106519A2/de
Publication of WO2004106519A3 publication Critical patent/WO2004106519A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Mrp8/Mrp14 hihibitoren zur Herstellung eines Medikaments zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden. Ferner betrifft die Erfindung neuartige Mrp8 oder Mrp 14 Inhibitoren, insbesondere siRNAs.
PCT/EP2004/006012 2003-06-03 2004-06-03 Mrp8/mrp14 inhibitoren und ihre verwendung zur prävention und/oder behandlung von hypertrophen narben und keloiden Ceased WO2004106519A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10324997A DE10324997A1 (de) 2003-06-03 2003-06-03 Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
DE10324997.4 2003-06-03

Publications (2)

Publication Number Publication Date
WO2004106519A2 WO2004106519A2 (de) 2004-12-09
WO2004106519A3 true WO2004106519A3 (de) 2005-01-20

Family

ID=33482418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006012 Ceased WO2004106519A2 (de) 2003-06-03 2004-06-03 Mrp8/mrp14 inhibitoren und ihre verwendung zur prävention und/oder behandlung von hypertrophen narben und keloiden

Country Status (2)

Country Link
DE (1) DE10324997A1 (de)
WO (1) WO2004106519A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5366077B2 (ja) * 2007-02-09 2013-12-11 株式会社 資生堂 炎症および過剰増殖を伴う皮膚疾患モデル
EP2379752B1 (de) 2009-01-19 2015-09-30 Biomérieux S.A. Verfahren zur bestimmung der anfälligkeit eines subjekts für eine nosokomiale infektion und zur prognose der entwicklung eines septischen syndroms
FR2941239B1 (fr) * 2009-01-19 2013-11-15 Biomerieux Sa Procede pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient presentant une reponse systemique inflammatoire associee ou non a une infection.
EP2943226B1 (de) 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutische zusammensetzungen und verfahren mit mrna-transfektion
CN104293788A (zh) * 2014-10-14 2015-01-21 广西医科大学 抑制S100A9基因表达的siRNA及其应用
CN104293789A (zh) * 2014-10-14 2015-01-21 广西医科大学 抑制S100A8基因表达的siRNA及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088181A2 (en) * 2001-04-30 2002-11-07 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK NCBI; 12 September 1993 (1993-09-12), ODINK, K. ET AL.: "Human mRNA for calcium-binding protein in macrophages (MRP-14)", XP002299027, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV Database accession no. X06233 *
DATABASE NUCLEOTIDE [online] NCBI; 12 September 1993 (1993-09-12), DORIN, J.R. ET AL.: "Human mrNA for cystic fibrosis antigen (CFAg)", XP002299028, Database accession no. Y00278 *
LI CONG ET AL: "Induction of S100A9 Gene Expression by Cytokine Oncostatin M in Breast Cancer Cells Through the STAT3 Signaling Cascade.", BREAST CANCER RESEARCH AND TREATMENT. SEP 2004, vol. 87, no. 2, September 2004 (2004-09-01), pages 123 - 134, XP002298482, ISSN: 0167-6806 *
THOREY IRMGARD S ET AL: "The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35818 - 35825, XP002298481, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
DE10324997A1 (de) 2004-12-23
WO2004106519A2 (de) 2004-12-09

Similar Documents

Publication Publication Date Title
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2003080582A3 (de) Fredericamycin-derivate
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2006084131A3 (en) Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2004006858A3 (en) Compounds, compositions, and methods employing same
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
EP1691842A4 (de) Behandlung von proliferativen erkrankungen mit einem antisense-iap-oligomer und einem chemotherapeutischen mittel
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
WO2002028434A3 (en) Use of a ppar delta activator for treating inflammatory conditions
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2005105829A3 (en) Caspase-2 inhibitors and their biological applications
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2004084932A3 (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
WO2005023191A3 (en) Rage-related methods and compositions for treating glomerular injury
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
TW200637542A (en) Lipase inhibitor, preventing and treating agent of skin disease
WO2004112690A3 (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 69(1) EPUE (EPA FORM 1205A) VOM 10.02.2006

122 Ep: pct application non-entry in european phase